Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 106.72M P/E - EPS this Y 55.40% Ern Qtrly Grth -
Income -78.91M Forward P/E -1.38 EPS next Y 12.70% 50D Avg Chg -7.00%
Sales 19.64M PEG - EPS past 5Y - 200D Avg Chg -14.00%
Dividend N/A Price/Book 0.94 EPS next 5Y - 52W High Chg -53.00%
Recommedations 1.50 Quick Ratio 1.10 Shares Outstanding 100.09M 52W Low Chg 14.00%
Insider Own 3.88% ROA -17.30% Shares Float 71.46M Beta 3.23
Inst Own 14.77% ROE -64.37% Shares Shorted/Prior 363.59K/395.43K Price 1.92
Gross Margin 96.25% Profit Margin - Avg. Volume 61,158 Target Price 7.00
Oper. Margin -181.11% Earnings Date Nov 4 Volume 48,619 Change -4.48%
About Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis S.A. News
11/06/24 Monthly information on share capital and company voting rights
11/05/24 Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
11/04/24 Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
10/30/24 Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
10/23/24 Cellectis Presents New Gene-Editing Breakthroughs
10/22/24 Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
09/20/24 CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
09/03/24 Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
08/26/24 Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
08/07/24 Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
08/06/24 Cellectis Provides Financial Results for the Second Quarter 2024
08/02/24 Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia
08/01/24 FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
07/25/24 FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
07/12/24 Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
07/10/24 Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)
06/28/24 Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
06/20/24 Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
06/18/24 Cellectis (CLLS) Upgraded to Buy: Here's Why
06/18/24 After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
CLLS Chatroom

User Image rlkloehn Posted - 6 days ago

$CLLS busy schedule The EBTT 2024 Conference (Electroporation-Based Technologies and Treatments) will take place November 11-16, 2024 in Ljubljana, Slovenia. The Jefferies London Healthcare Conference will take place November 19-21, 2024 in London, UK. André Choulika, Chief Executive Officer, and Arthur Stril, Interim Chief Financial officer, will participate and host meetings with investors. The Citizens JMP Hematology and Oncology Summit will take place virtually on Monday, December 2, 2024. Arthur Stril, Interim Chief Financial Officer, and Adrian Kilcoyne, Chief Medical Officer, will participate in a fireside chat at 1.00 PM ET The 7th Annual Evercore ISI HealthCONx Conference will take place on December 3-5, 2024 in Coral Gables, Florida. Arthur Stril, Interim Chief Financial Officer, will participate in a fireside chat December 3, 2024 at 1:45 PM The 6th Annual Cell Therapy Analytical Development Summit will take place December 3-5, 2024 in Boston, USA.

User Image Nundanodima Posted - 1 week ago

"💥 Boom 🚨 $CLLS $AVTX — let’s crush these short sellers. This is massive news: MYNZ (mkt cap $7M) teaming up with TMO (mkt cap $209B). You don’t often see a collab like this! Another big PR is definitely on the way, and this is set to take off. Place your order all at once at 1 PM NY time, make a splash, and push the short sellers out."

User Image justiceforb_85 Posted - 1 week ago

$CRGX are they furthest along in CD22-targeted CAR-T cell therapy for lymphoma? Appears $CLLS is also in the mix but their product isn't as far along?

User Image StayYou Posted - 2 weeks ago

$CLLS my thoughts is this staying nice and low for years to come thanks to that Collaboration with Astra Zeneca. These guys have 25 targets to get through. Cellectis plays an integral role here now that it controlled by Astra Zeneca with its now 44 percent controlling stake. So good. Delusional K

User Image StayYou Posted - 2 weeks ago

$CLLS Great to hear wang. I don’t see what you see. But great work. I see lots of value here. The cash alone is great. It’s just sitting there doing nothing. Must be burning a hole in their pocket. So much cash with no purpose but to sit for three years. Never heard of a company that could just sit on cash and slowly bleed for three years. They just be waiting for something. Lots of rollovers to do. I’m still trying to get my puppy to rollover. Cuckoo Penny

User Image jewell69 Posted - 2 weeks ago

Analyst Gena Wang from Barclays maintained a Buy rating on Cellectis SA (CLLS), with a $5 price target. 11/5/2024 $CLLS Cellectis price target lowered by $2 at Barclays, here's why Barclays lowered the firm's price target on Cellectis to $5 from $7 and keeps an Overweight rating on the shares following the Q3 report.

User Image StayYou Posted - 2 weeks ago

$CLLS I think it’s going to get pretty quiet now for the next four years. Most of these projects will need to wound down by then. Immunis hasnt even begun to reach for public hand outs. Myriad genetics is obviously still working the public coffers. They need the money to get things done. Then they will slowly bring things down to a nice speed. Success is bankruptcy like Immune Pharmaceuticals and Humanigen. I could’ve bet on Humanigen. That was a no brainer. The way Cameron shot for the door and went over there was a tell sign. He‘s shit bag you need to get things done. All you have to do is listen to that prick talk. He’s a human garbage disposal like the rest of those fund managers. Astra Zeneca has all these twats working hard at doing nothing for the next 4 years. Hilarious. You have to laugh. These guys are doing fuck all. Zip. Nothing. Funny times.

User Image StayYou Posted - 2 weeks ago

$CLLS This Russian Squirrel on cocaine running this Cellectis has been a busy boy. 25 targets would be a fun project if I was on speed as well. Lucky for him he has 4 years to do it all in. He has spread the love pretty nicely.

User Image StayYou Posted - 2 weeks ago

$CLLS I’m not surprised that Humanigen is part of the 25 targets that will be rolled up like Immune pharmaceuticals. Humanigen was brought bankruptcy which I knew it would be. Cameron Durant is buddies with Daniel Teper. Cameron was vice chairman of Immune Pharmaceuticals. A royal piece of shit. The thing with my view is that I mean it. most people like these guys. I find them disposable human pieces of trash. All working for Big Momma. Sucking of the teets of Momma while stealing peoples money. Yup. Royal assholes.

User Image StayYou Posted - 2 weeks ago

$CLLS Cash runway lines us up with the 2028 timeline for role up to complete. Cytovia Therapeutics , Naya Bioscience, Satellos Bioscience and a few others like Immunis , Myriad Genetics and Immune Pharmaceuticals, Maxim Pharmaceuticals should all be rolled up by then into Astra Zeneca. I guess Cellectis will take the lead role there. I wonder how all these are going to come together. 25 targets all together. I’m trying to list the targets. So many to go.

User Image StayYou Posted - 2 weeks ago

$CLLS Cash position of $264 million as of September 30, 20241; cash runway projection into 2027

User Image rlkloehn Posted - 2 weeks ago

$CLLS “Additionally, we are excited to announce that research and development activities have started for three programs under our collaboration and research agreement with AstraZeneca: one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder.

User Image DonCorleone77 Posted - 2 weeks ago

$CLLS Cellectis reports Q3 EPS (22c), consensus (21c) Reports Q3 revenue $18.05M, consensus $5.4M. "This quarter, we were thrilled to welcome Dr. Kilcoyne to Cellectis as Chief Medical Officer. Dr. Kilcoyne joins us at a pivotal time for the Company, bringing extensive experience in drug development as we are progressing in our clinical programs. We expect to present Phase 1 dataset and late-stage development strategy in 2025 for UCART22 in ALL and UCART20x22 for NHL" said Andre Choulika, CEO at Cellectis.

User Image StayYou Posted - 2 weeks ago

$CLLS 2028 it all comes together. Maybe sooner folks. Astra Zeneca is Big Momma and she is looking for 25 targets. Keep buying here folk. Dont sell people. Keep building your beneficial holdings. You eventually will own a much bigger company And it ain’t Cellectis. Russian boy is pawn. A fund manager doing what he’s told. He has zero control. He’s a little bitch puppet. Just buy and hold. Enjoy. You have lots of time to play the range. Easy spread for all you traders. Cuckoo Penny

User Image StayYou Posted - 2 weeks ago

$CLLS Yes I agree. But maybe Astra Zeneca keeps it alive to complete the final merger. Maybe it’s with Cytovia Therapeutics or maybe they plan it to go to zero and delist, deregister without winding down and then merge with another public company or maybe they just dissolve it into Astra once all done. stay tuned big guy. Cuckoo Penny

User Image grinchspan Posted - 10/31/24

$CLLS on its way to 0

User Image StayYou Posted - 10/26/24

$CLLS Hey folk. I made a mistake in last post. Don’t know why I wrote SOAC after ESHA. I believe it was auto correct issue. So for people that read post, please excuse, I meant to say ESHA SPAC Merger to come. I understand though that some SPACs have been given that 6 month extension based on whatever reason. Have a wonderful day. Stay you. Crazy K

User Image StayYou Posted - 10/25/24

$CLLS Stay strong people. Lots to come over the next 4-5 years. Astra Zeneca is in control. Play the lows and the highs. All these CEOs are simply fund managers . Look out for Cytovia Therapeutics. Look out for Naya Bioscience And BioXCell and CytoLynx. All connected and all controlled by Astra Zeneca. ESHA SOAC merger to come with someone needing 116 million thats held in trust. Allan Weiss is involved as he was with Isleworth healthcare and it’s merger with Cytovia. Lots of heavy breathers like Jack Ma and his fund who is involved with Cytolynx which is controlled sub of Cytovia Therapeutics. That’s run by Daniel Teper and Steve Shum who are the devils in disguise. They are simply fund managers managing your money. The Russia squirrel that runs Cellectis is a fund manager as well. He’s a nobody that simply wants to steal your hard earned cash. Collaboration consists of 25 targets spread out over next 4-5 years. No liquidity for legacy shareholders for the Independent targets. These guys will bankrupt some of the future targets to make it easier to fund the project by crooked institutions. You the know kind. TD bank is an example of just one of the many institutions in billion dollar laundering scams. All will catch up to everyone eventually. You live a dishonest life. You will pay. Some just pay fines but others go to jail. Fight the system with knowledge. Educate to elevate people. Make a profit while these guys eat themselves and others to achieve their goals. Stay strong. Stay You. Truth is generally seen rarely heard. Cuckoo Penny

User Image rlkloehn Posted - 10/23/24

$CLLS https://www.cellectis.com/en/press/cellectis-to-present-data-on-tale-base-editors-and-non-viral-gene-therapy-at-the-esgct-31st-annual-congress/

User Image Stocks4thought Posted - 10/23/24

$CLLS Bullpen active?

User Image mikefbi Posted - 1 month ago

$CLLS Letterpenny, Letterkenny Pennyworth, etc. you are one dishonest individual, who got caught lying. Mendacious is another name for you. The records clearly show that you lied and provided false & misleading statements Wonder if using pseudonyms and posting positive statements to receive benefits. You are a fool and a loser just looking for attention. You will never catch up to me because you are a degenerate. Four words describe you the best: Delusional Denial Narcissists And Circumlocution Take your 17 million worthless shares which you are devastated with the loss. That's where you belong right

User Image StayYou Posted - 1 month ago

$CLLS MikeBear, maybe you can solicit the 48 to 49 followers who are obviously the dumbest Bot shits on the block. I can’t seem to get rid of them. You are one of them MikeBear. You have explained over and over again that I’m a liar and I’m here to serve my own needs. This is all true. Maybe just try to cancel me. Maybe report me to your Bearboard like last time. That seemed to work. Cancelling works. It doesn’t work on me but it does help your goal. Little Bearbitches do that method. This way you solve your problem. Does that sound good MikeBear?!

User Image StayYou Posted - 1 month ago

$CLLS I knew you were Scamstock guy. A shitty trader. Now I understand why you are so disturbed and are still following me. hilarious. Someone needs a Bearhug. Little BooBoo Bear is hurting. That character loves the men’s showers just as MikeBear does. I’m so good at this shit. It’s like making music. Too easy. Everyone has a flow in their speech. Boy did I destroy that little bitch scamstock character. Hilarious. Thanks for the memories. I am what I am I’m Popeye the sailor man. Shake your thang. Shake it MikeBear. I know what you want.

User Image mikefbi Posted - 1 month ago

$CLLS Hairy Bear Pennyworth etc New name same type of posting Keep posting misleading and false statements it makes you look so foolish. You need the attention to feel important. Cut and paste that you do is selected and omits the facts. Cytovia Therapeutics and Cellectis partnership ended and Cytovia Therapeutics is in debt to Cellectis for failure to comply with the said agreement you got suckered into believing everything that Dr.Teper and the company posted Your alleged 17 million shares are worthless Like yourself, feel sorry for you, look to a higher power for direction and help. You are a revolting person for deliberately posting false information for the benefit of your ego. Whoever believes in you is a fool for sure another new name coming soon. Your most famous statements are: I NEVER LOSE ..... I HELP PEOPLE .... I WILL SUE .... Etc ... All of the above was posted to mislead (lied) and increase your ego. Maybe no one now is listening to you which will be a blessing

User Image StayYou Posted - 1 month ago

$CLLS Thanks Cellectis for supporting ESG. This world needs to treat all Bears equal right Mike? Bears are here no matter how hairy the market gets. So awesome Mike. Thanks for following me. It means so much. HairyBear has your back no matter what happens. Go Cellectis!

User Image StayYou Posted - 1 month ago

$CLLS Bears are welcome on this board. This board supports and loves Bears like Mike. Don’t forget to cut and paste my posts. Super duper excited. Hercules. Hercules. Hercules.

User Image StayYou Posted - 1 month ago

$CLLS Who doesn’t love a Bear. Stay shaggy. Stay you. The other Bears love a crazy Bear. Cuckoo Penny

User Image StayYou Posted - 1 month ago

$CLLS Hey Bear. Why you so down on Cellectis? Stay strong Bear.

User Image StayYou Posted - 1 month ago

$CLLS Cellectis has a partner and guess who that is. I will give you a guess. It owns 44 percent of the Cellectis. Guess who Bear.

User Image StayYou Posted - 1 month ago

$CLLS What do you think people? 15 million cash payment to private company. They just keep us guessing, eh Bear.

Analyst Ratings
Oppenheimer Outperform Jun 12, 24
JMP Securities Market Outperform May 31, 24
JMP Securities Market Outperform Nov 1, 23
Oppenheimer Outperform Aug 8, 23
JMP Securities Market Outperform Aug 7, 23
Citigroup Buy Apr 5, 23
Oppenheimer Outperform Mar 13, 23
JMP Securities Market Outperform Mar 13, 23
JMP Securities Market Outperform Jan 19, 23